ACHE and Alzheimer disease: Even though some small molecules, such as acetylcholinesterase inhibitors and memantine, which are approved for the treatment of AD, can cross the BBB and enter the brain parenchyma, >98% of small molecules do not cross the BBB [45]; therefore, their biological activity is suboptimal [46,47,48], presenting a challenge for the development of CNS therapies [49].